IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS)
e-ISSN:2278-3008, p-ISSN:2319-7676. Volume 20, Issue 5 Ser. 1 (Sep. – Oct. 2025), PP 29-34
www.iosrjournals.org

"Medicinal Plants: A Bridge Between Traditional Knowledge and Modern Science."

Suniti Bala Chandra
Research scholar, Department of Botany
Radha Govind university. Ramgarh. Ranchi Jharkhand

Abstract
Medicinal plants have served as the cornerstone of healthcare across civilisations for millennia, forming an indispensable part of traditional medical systems such as Ayurveda, Unani, Siddha, and Traditional Chinese Medicine. In contemporary times, their role has expanded beyond ethnobotanical traditions into mainstream pharmaceutical research and drug discovery. Approximately 80% of the world's population continues to rely on plant-based remedies for primary healthcare needs (WHO, 2013, p. 4), while modern science increasingly recognises the pharmacological potential of bioactive compounds derived from medicinal plants.
This article explores the relationship between traditional knowledge and modern science, positioning medicinal plants as a bridge that connects indigenous wisdom with contemporary healthcare innovations. It begins with an analysis of ethnomedicinal practices, moving towards bioprospecting and pharmacological research that transforms traditional remedies into modern drugs. The article highlights the socio-economic, cultural, and ecological significance of medicinal plants, while also examining challenges such as overexploitation, intellectual property rights (IPR), biopiracy, and conservation.
Global and Indian case studies—including Artemisia annua (source of artemisinin for malaria treatment), Catharanthus roseus (rosy periwinkle for cancer therapy), Azedarach indica (neem for antifungal and antibacterial uses), Curcuma longa (turmeric for anti-inflammatory properties), and the Hoodia cactus (used by San communities for appetite suppression)—illustrate the journey of medicinal plants from traditional remedies to validated scientific products. The article also analyses international policy frameworks such as the Convention on Biological Diversity (CBD), the Nagoya Protocol, and India's Biodiversity Act 2002, which govern access, benefit-sharing, and conservation of medicinal plant resources.
It concludes that medicinal plants serve not only as therapeutic agents but also as cultural connectors, ecological assets, and economic resources. By integrating traditional knowledge systems with modern scientific research and policy frameworks, medicinal plants can continue to serve as a bridge between the wisdom of the past and the innovations of the future.

Keywords:
Medicinal plants, Traditional knowledge, Pharmacology, Bioprospecting, Biodiversity, Intellectual property rights, Ayurveda, Conservation, Modern science, Drug discovery

I. Introduction;

Medicinal plants are a vital resource at the intersection of culture, ecology, and science. Since ancient times, plants have been utilised for their therapeutic properties, forming the basis of traditional medical systems across the globe. Indian Ayurveda, Chinese medicine, African ethnomedicine, and Native American healing practices all underscore the centrality of plants in healthcare. In recent decades, the pharmaceutical industry has rediscovered this reservoir of knowledge, validating many traditional practices through scientific methodologies and extracting active compounds for modern medicine.

Modern science and traditional knowledge are often viewed as distinct systems of thought. However, medicinal plants demonstrate how these systems can intersect. While traditional knowledge provides a holistic understanding of plants within cultural and ecological contexts, modern science contributes rigorous methods of analysis, isolation, and clinical validation. This convergence has produced groundbreaking drugs such as artemisinin for malaria and vincristine for leukaemia, both derived from plants with long-standing traditional use.

This article examines how medicinal plants function as a bridge between traditional and modern medicine. It explores ethnobotanical traditions, pharmacological breakthroughs, global and Indian case studies, and the policy landscape, while also addressing the challenges of biopiracy, conservation, and equitable benefit-sharing.

II. Traditional Knowledge and Ethnomedicine;

Traditional knowledge refers to the collective wisdom and practices developed by indigenous and local communities over centuries. It is embedded within cultural, spiritual, and ecological frameworks. Medicinal plants form a substantial part of this knowledge, offering remedies for a wide range of ailments.

In India, Ayurveda employs more than 1,500 medicinal plants, including neem (Azedarach indica), turmeric (Curcuma longa), and ashwagandha (Withania somniferous). Similarly, Traditional Chinese Medicine (TCM) uses approximately 5,000 plant species, including ginseng (Panax ginseng) and licoricey (Glycyrrhiza glabra). African and Latin American indigenous communities also maintain extensive pharmacopeia's based on local flora.

Ethnomedicine is more than an empirical system; it reflects an integrative worldview in which plants are understood not only for their pharmacological properties but also for their symbolic and cultural meanings. However, the empirical efficacy of many traditional remedies has been validated by modern pharmacological research, confirming the depth of indigenous knowledge.

III. From Traditional Remedies to Modern Drugs: Bioprospecting and Pharmacology;

The transition of medicinal plants from traditional remedies to scientifically validated drugs involves bioprospecting—the systematic search for biologically active compounds in natural resources. Modern pharmacology employs advanced tools such as chromatography, spectroscopy, and molecular docking to isolate and characterise bioactive constituents.

For example, the antimalarial drug artemisinin, derived from Artemisia annua, was first identified in traditional Chinese medicine as a treatment for fevers. Similarly, the cancer drugs vinblastine and vincristine originate from Catharanthus roseus (rosy periwinkle), a plant used in Indian folk medicine. Turmeric's active compound, curcumin, has been scientifically validated for its anti-inflammatory and antioxidant properties.

Bioprospecting highlights the complementarity of traditional knowledge and modern science. While traditional practices guide researchers towards promising plants, scientific methods provide the precision required for drug development. However, this also raises ethical questions about intellectual property rights and benefit-sharing, particularly when pharmaceutical companies profit from indigenous knowledge without proper recognition or compensation.

IV. Biodiversity and Conservation of Medicinal Plants;

The World Health Organization (WHO, 2013, p. 12) estimates that around 21,000 plant species have medicinal uses. Yet, unsustainable harvesting, deforestation, and climate change threaten many of these species. The International Union for Conservation of Nature (IUCN) lists several medicinal plants, such as yew (Taxus baccate) and wild ginseng, as endangered.

India is one of the world's richest centres of medicinal plant diversity, with over 7,000 documented species. The Himalayas, Western Ghats, and forests of Northeast India are particularly abundant. However, commercial demand for plants like ashwagandha, Sarpa Gandha (Rauwolfia serpentina), and sandalwood has led to overexploitation.

Conservation strategies include in situ protection through biosphere reserves and national parks, and ex situ methods such as seed banks and botanical gardens. India's National Medicinal Plants Board (NMPB) plays a pivotal role in promoting cultivation, conservation, and sustainable harvesting. Globally, the Convention on Biological Diversity (CBD, 1992) and the Nagoya Protocol (2010) provide frameworks for conserving biodiversity while ensuring equitable benefit-sharing.

V. Intellectual Property Rights, Biopiracy, and Benefit-Sharing;

The growing commercial interest in medicinal plants has generated debates about intellectual property rights (IPR) and biopiracy. Biopiracy occurs when corporations exploit traditional knowledge without proper authorisation or benefit-sharing.

Notable cases include the U.S. patent on neem extracts for antifungal properties, which was later revoked after legal challenges from Indian scientists and activists (Shiva, 1997, p. 62). Similarly, attempts to patent turmeric for wound healing faced opposition from India's Council of Scientific and Industrial Research (CSIR), which demonstrated that turmeric had long been used in Indian traditional medicine.

The Nagoya Protocol (2010) established international guidelines for access to genetic resources and equitable sharing of benefits. In India, the Biological Diversity Act (2002) and the Traditional Knowledge Digital Library (TKDL) aim to safeguard indigenous knowledge from misappropriation. Such frameworks ensure that local communities benefit when their knowledge contributes to pharmaceutical innovation.

VI. Case Studies: Medicinal Plants in Practice;

Medicinal plants serve as crucial bridges between traditional knowledge systems and modern pharmacological science. They exemplify how centuries of indigenous practice, when investigated with rigorous scientific methods, can yield discoveries of global medical significance. At the same time, they highlight tensions between commercialisation, intellectual property, and community rights. The following case studies present well-documented examples of medicinal plants whose trajectories—from traditional contexts to global therapeutics—demonstrate the potential, challenges, and ethical complexities of plant-based medicine.

6.1 Artemisinin (Artemisia annua) – China;

The discovery of artemisinin marked one of the most significant breakthroughs in twentieth-century medicine. Extracted from Artemisia annua, commonly known as sweet wormwood, the compound revolutionised the treatment of malaria, a disease responsible for millions of deaths across the tropics. Although Artemisia had been used in traditional Chinese medicine for centuries, it was Tu Youyou's systematic research in the early 1970s, under Project 523 during the Cultural Revolution, that isolated artemisinin as the active antimalarial argentite Youyou's approach combined a deep reading of ancient Chinese medical texts with modern extraction techniques. By lowering the temperature during the extraction process, she succeeded in preserving the plant's active properties. The subsequent development of artemisinin-based combination therapies (ACTs) has saved millions of lives worldwide and remains the World Health Organization's frontline treatment for malaria.

In 2015, Tu You you was awarded the Nobel Prize in Physiology or Medicine, becoming the first Chinese woman to receive the award. Beyond its medical triumph, the case of artemisinin illustrates how traditional plant knowledge can catalyse modern pharmacological revolutions when supported by sustained scientific inquiry. It also underscores the importance of protecting and valuing indigenous knowledge, which provided the foundation for this discovery.

6.2 Rosy Periwinkle (Catharanthus roseus) – India and Madagascar

The rosy periwinkle, native to Madagascar but widely cultivated in India, is another striking example of how a seemingly ordinary plant can yield life-saving compounds. In Indian folk medicine, Catharanthus roseus was traditionally used as a remedy for diabetes. However, it was in the 1950s that scientists isolated two alkaloids from the plant—vinblastine and vincristine—that transformed the treatment of cancer.Vinblastine and vincristine inhibit cell division, making them particularly effective in chemotherapy for childhood leukaemia and Hodgkin's lymphoma. Before their discovery, survival rates for childhood leukaemia were extremely low. Today, thanks to drugs derived from periwinkle, survival rates exceed 80% in many countries.

This case is also emblematic of the tensions around bioprospecting and intellectual property. The commercial success of periwinkle-derived drugs brought enormous profits to pharmaceutical companies in North America and Europe, yet neither Madagascar nor India initially received equitable recognition or compensation. The case has since become a touchstone in debates on biopiracy and the need for frameworks such as the Convention on Biological Diversity (1992) and the Nagoya Protocol (2010), which emphasise fair and equitable benefit sharing.

6.3 Neem (Azadirachta indica) – India

Neem, often called the "village pharmacy" in India, has occupied a central place in Ayurvedic medicine for centuries. Its antibacterial, antifungal, and antiviral properties have made it a versatile remedy for skin diseases, infections, and inflammation. Beyond medicine, neem products have long been used in agriculture as

natural pesticides, in cosmetics, and in personal hygiene products. The neem tree became a global symbol in the 1990s when a patent dispute in Europe highlighted the dangers of biopiracy. A US company was granted a patent for neem-based fungicidal products, which led to widespread protests by Indian scientists, farmers, and activists. They argued that the medicinal and pesticidal uses of neem had been known in India for millennia, and thus could not be treated as novel inventions. In 2000, the European Patent Office revoked the patent after determining that neem's properties were indeed prior knowledge.

This case became a landmark in the international discourse on intellectual property rights, indigenous knowledge, and biodiversity conservation. It demonstrated that protecting traditional knowledge is essential not only for cultural integrity but also for ensuring that global pharmaceutical and agricultural industries do not profit unfairly from community heritage. Today, neem continues to inspire research into eco-friendly biopesticides and plant-based pharmaceuticals, standing as a symbol of the convergence between ancient wisdom and modern science.

6.4 Turmeric (Curcuma longa) – India;

Turmeric has been a cornerstone of Indian cuisine, ritual, and medicine for thousands of years. Its primary bioactive compound, curcumin, has attracted global scientific attention for its anti-inflammatory, antioxidant, and potential anticancer properties. Traditionally, turmeric paste was applied to wounds, burns, and skin infections, while turmeric milk and decoctions were consumed to boost immunity and digestion.

In the 1990s, turmeric also became the centre of a controversial patent dispute when two American researchers were granted a US patent for the use of turmeric powder in wound healing. Indian scientists and the Council of Scientific and Industrial Research (CSIR) contested the patent by providing centuries-old Ayurvedic references documenting this use. The US Patent and Trademark Office revoked the patent in 1997, acknowledging the traditional knowledge base.

Today, turmeric supplements are marketed globally, ranging from capsules to cosmetics, and research into curcumin continues in oncology, neurology, and cardiology. However, challenges remain in improving curcumin's bioavailability in the human body, leading to ongoing innovation in drug delivery systems. The turmeric case once again illustrates the importance of safeguarding indigenous knowledge and ensuring that benefits derived from it are shared equitably.

6.5 Hoodia (Hoodia Gordini) – Southern Africa

The story of Hoodia Gordini, a cactus-like succulent native to the Kalahari Desert, highlights not only the potential of medicinal plants but also the ethical dilemmas surrounding bioprospecting. For centuries, the San people of Southern Africa chewed Hoodia stems to suppress hunger and thirst during long hunting trips.

In the late 20th century, researchers identified the plant's active compound, P57, which was licensed to pharmaceutical companies as a potential weight-loss drug. However, the initial patents and profit structures completely excluded the San people, whose knowledge had led to the discovery. After widespread criticism and international advocacy, agreements were finally established to share benefits with the San community.

The Hoodia case underscores the ethical dimension of medicinal plant research. While it demonstrates the vast pharmaceutical potential embedded in indigenous practices, it also highlights the dangers of exploitation without recognition or compensation. The eventual benefit-sharing agreements marked progress, but they came only after sustained resistance, revealing the power imbalances in global pharmaceutical innovation.

6.6 Comparative Insights;

Together, these five case studies illustrate the multifaceted role of medicinal plants. On the one hand, they underscore the power of traditional knowledge in shaping modern pharmacology—saving millions of lives in the process. On the other hand, they reveal persistent global inequities in knowledge recognition, intellectual property rights, and benefit sharing.

Artemisinin and periwinkle show how traditional remedies can evolve into mainstream therapeutics through rigorous scientific validation. Neem and turmeric demonstrate the need to protect indigenous knowledge from biopiracy, reminding us that ancient practices should not be commodified without acknowledgement. Hoodia, finally, highlights the ethical imperative of ensuring community participation and benefit-sharing in medicinal plant research.

Taken together, these narratives reinforce the broader argument that medicinal plants are not merely biological resources but also cultural assets, ethical challenges, and political actors in the global health landscape. Protecting them requires not only scientific investment but also robust legal frameworks and respect for the communities that have nurtured this knowledge across generations.

VII. Policy Frameworks and Global Governance;

Medicinal plants are governed by complex international and national policies. The CBD (1992) and the Nagoya Protocol (2010) emphasise conservation, sustainable use, and equitable sharing of benefits. The World Health Organization also promotes the integration of traditional medicine into national healthcare systems (WHO, 2013, p. 28).In India, the Ministry of AYUSH promotes Ayurveda, Yoga, Unani, Siddha, and Homeopathy, while the National Medicinal Plants Board coordinates conservation and commercial cultivation. The Indian Patents Act (1970, amended in 2005) and the TKDL safeguard traditional knowledge from exploitation.

However, policy implementation faces challenges such as lack of documentation, insufficient funding for conservation, and conflicts between community rights and corporate interests. Stronger collaboration between governments, researchers, and communities is essential to achieve the goals of conservation and equitable benefit-sharing.

VIII. Challenges in Integration;

Despite their promise, medicinal plants face challenges in bridging traditional and modern science. These include:
Scientific validation: Many traditional remedies lack clinical trials, making integration into modern medicine difficult.
Standardisation: Variability in plant chemistry due to soil, climate, and cultivation methods complicates dosage and efficacy.
Overexploitation: Commercial demand threatens plant populations and biodiversity.
Ethical concerns: Issues of biopiracy and inequitable benefit-sharing persist. Healthcare integration: Modern medicine often undervalues traditional knowledge, leading to parallel rather than integrated systems. Addressing these challenges requires interdisciplinary collaboration, robust policy support, and investment in research.

IX. Conclusion;

Medicinal plants embody the confluence of traditional knowledge and modern science. They are not only therapeutic agents but also cultural symbols, ecological assets, and economic resources. From Artemisia annua in China to neem and turmeric in India, case studies illustrate how indigenous wisdom has informed breakthrough drugs.

However, the bridge between traditional and modern science is fragile, threatened by overexploitation, biopiracy, and inadequate recognition of indigenous contributions. To strengthen this bridge, policies must prioritise biodiversity conservation, protect community rights, and promote equitable benefit-sharing. Scientific research should engage with, rather than dismiss, traditional knowledge, ensuring rigorous validation while respecting cultural contexts.

As global health challenges such as pandemics, antibiotic resistance, and chronic diseases intensify, medicinal plants offer an invaluable resource for innovation. By uniting the wisdom of the past with the methods of the present, medicinal plants can continue to shape the future of healthcare, embodying a truly integrative and sustainable approach.

References

[1]. Convention on Biological Diversity (CBD). (1992). Convention on Biological Diversity. United Nations. p. 8.
[2]. Gupta, R., & Sharma, V. (2019). Traditional knowledge and bioprospecting: Challenges and opportunities. Journal of Ethnopharmacology, 243, 111–121. p. 114.
[3]. International Union for Conservation of Nature (IUCN). (2020). Red List of Threatened Species. IUCN. p. 36.
[4]. Nair, P. K. R. (2012). Carbon sequestration studies in agroforestry systems: A reality-check. Agroforestry Systems, 86(2), 243–253. p. 246.
[5]. National Medicinal Plants Board (NMPB). (2021). Annual report. Ministry of AYUSH, Government of India. p. 42.
[6]. Shiva, V. (1997). Biopiracy: The plunder of nature and knowledge. South End Press. p. 62.
[7]. Tu, Y. (2011). The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nature Medicine, 17(10), 1217–1220. p. 1218.

[8]. United Nations Convention to Combat Desertification (UNCCD). (2016). The Great Green Wall: Implementation status and way ahead to 2030. p. 19.
[9]. World Health Organization (WHO). (2013). WHO traditional medicine strategy 2014–2023. WHO Press. p. 4, p. 28.
[10]. Zohara, Y., & Farnsworth, N. R. (1994). Economic botany: Plants in the human life. McGraw Hill. p.11.Pushpangadan, P., & George, V. (2010). Ethnomedicinal plants: Biodiversity, conservation and sustainable utilisation. Indian Journal of Traditional Knowledge, 9(1), 15–25. p. 18.
[11]. Patwardhan, B., & Mashelkar, R. A. (2009). Traditional medicine-inspired approaches to drug discovery: Can Ayurveda show the way forward? Drug Discovery Today, 14(15–16), 804–811. p. 807.
[12]. Singh, R. H. (2017). Ayurveda: The science of life. Cha Ukhamba Sanskrit Pratishtha. p. 101.
[13]. Kumar, A., & Tiwari, P. (2020). Turmeric and its active principles: From traditional use to modern medicine. Phytotherapy Research, 34(1), 1–10. p. 5.